According to a press release issued by the state government, the expansion is primarily targeted to ramp up the manufacturing of vaccines a...

WHO along with its partners will work with the Indian government and BE to develop a roadmap and put in place the necessary training and su...

"Our price to the government programme is ₹145, the lowest in the country and possibly the world," Datla said. "It's something we take grea...

The government had estimated that Biological would account for 300 million jabs from August to December.

Speaking to reporters on the sidelines of signing a financing agreement with US International Development Finance Corporation (DFC), she sa...

The approval for conducting phase III comparator safety and immunogenicity trial in adults came after the SEC's review of Phase I and II cl...

"Met Ms Mahima Datla, MD of @Biological_E , who briefed me on the progress of their upcoming #COVID19 vaccine, Corbevax. I assured all the ...

Of these, the phase-three trials of Corbevax — jointly manufactured by BE, Baylor College of Medicine in Houston and Dynavax in California ...

Under the agreement, Providence will provide the necessary technology transfer for Biological E to manufacture mRNA vaccines in India with ...

Pending conditional regulatory approvals in India, BE expects to commence product launch of Corbevax later this year.

In all, India has reported more than 11 million coronavirus infections, the highest number in the world after the United States, and about ...

Disclosing this in Hyderabad on Monday, managing director Mahima Datla said the company is currently evaluating four different formulations...

Biological E will produce J&J's vaccine at its vaccine production facilities and sell them both in India and export across various global m...

This week India overtook the US in daily addition of new COVID-19 cases. It is worrying. The World Health Organization says that the infect...

India is staring at the risk of losing its competitive advantage in vaccine manufacturing to other countries, Biological E chairperson said...

Vaccine company Biological E plans to raise about Rs 620 crore by selling up to 25% stake to financial or strategic investors.

GAVI Alliance was created in 2000 to accelerate the introduction of new vaccines so that all children.